Aclarion's ACON Investments Divests Vitalis Stake, Highlighting Growth in Latin American Pharma
- ACON Investments successfully sold its stake in Colombian firm Vitalis S.A.C.I. to Laboratorios Sanfer.
- Under ACON's ownership, Vitalis expanded manufacturing and enhanced product offerings to over 700 registered items.
- ACON has a strong track record, successfully divesting 30 out of 44 investments in nearly three decades.
ACON Investments Successfully Divests Stake in Vitalis S.A.C.I.
ACON Investments, a private equity firm with a strong foothold in the Latin American market, announces the successful sale of its stake in Vitalis S.A.C.I., a Colombian producer of injectable pharmaceuticals, to Laboratorios Sanfer, a significant player in Mexico's pharmaceutical landscape. This strategic move marks a significant milestone for ACON, which acquired Vitalis in 2021 and has since driven substantial growth within the company. Vitalis, headquartered in Bogotá, has solidified its position as a vital supplier of injectable products to hospitals, clinics, and drugstores throughout the region.
Under ACON's ownership, Vitalis has greatly expanded its manufacturing capabilities and upgraded its facilities to adhere to stringent environmental and social standards, reinforcing its commitment to quality and sustainability. The company has also broadened its product portfolio to over 700 registered offerings, reflecting a robust commitment to innovation and market responsiveness. Notably, Vitalis has enhanced its market presence through the establishment of new commercial channels and a strategic acquisition in Chile, positioning itself as a key player in Latin America’s pharmaceutical sector.
ACON's disciplined investment strategy plays a crucial role in driving value creation, allowing Vitalis to thrive even amid fluctuating market conditions. ACON Partner Alberto Hernández highlights the firm's adeptness in navigating challenges, making it a valuable partner for companies seeking to grow. This recent sale follows ACON's successful exits from Brazilian investments, Dorí Alimentos S.A. and Conexão Group, which occurred in 2023 and 2024, respectively. With nearly three decades of experience in the region and a proven track record of successfully divesting 30 out of 44 investments, ACON continues to establish itself as a leader in private equity across Latin America.
In addition to the Vitalis transaction, ACON's financial and legal advisory support underscores the complexity and significance of the deal. While the specific terms of the transaction remain undisclosed, the involvement of BTG Pactual for financial advisory, alongside legal assistance from Brigard Urrutia and Hogan Lovells, highlights the strategic importance of this sale within the broader pharmaceutical landscape. ACON manages $7.2 billion in assets, focusing on investments in the U.S., Latin America, and Europe, and remains committed to identifying growth opportunities within the diverse and evolving pharmaceutical market.
This divestment not only showcases ACON's successful investment strategy but also signals a continued evolution within the Latin American pharmaceutical industry as companies like Vitalis adapt to meet increasing demand for high-quality injectable products.